Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient
Phase III Clinical Trial Company Uses Universal Donor Stem Cell to Suppress Brain Inflammation for Multiple Neurological Conditions
October 24, 2022 09:00 AM Eastern Daylight Time
ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) announced today successful administration of JadiCells into a treatment resistant epilepsy patient resulting in a profound recovery.
The patient was treated under the Right to Try Act as a result of preclinical data demonstrating significant advantage of JadiCells™ compared to standard umbilical cord mesenchymal stem cells in the pilocarpine-induced animal model. The company has filed a patent application covering the use of JadiCells™ for treatment of epilepsy and associated conditions.
“The patient had a history of epilepsy since the age of 28, leading to a life of crippling seizures and severe chronic tinnitus. The patient preferred to live in darkness for years due to any form of sound triggering violent seizures. The patient reported that he had not seen a movie, read a book or stepped out of his home for 35 years. We treated this patient with four regimens of JadiCell stem cells. In the first follow-up on Day 3 after treatment, he was feeling better and had not suffered a single seizure. By Day 7, he was watching his first movie and had begun to read his first book in decades. As of Day 20, after treatment, he was actually building a concrete flower container in his backyard and has not suffered a single seizure in three months,” said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor on the filed patient.
JadiCells™ are subject of a Phase III trial that the Company is performing for treatment of COVID-19. Additionally, the cells have been granted IND numbers for chronic obstructive pulmonary disease1, and for Chronic Traumatic Encephalopathy2, for which the Company is working with the FDA to initiate clinical trials. The Company has also successfully treated 15 patients with CTE or COVID-19 under Right to Try and Emergency IND3.
“The difference between us and other biotech companies is our ability to rapidly translate scientific findings into preclinical studies and based on the preclinical studies to rapidly enter patient use in an efficient and ethical manner through the Right to Try Law,” said Timothy Dixon, President and CEO of the Company and co-inventor. “On behalf of Therapeutic Solutions International I am proud in congratulating Dr. Veltmeyer in not only the clinical aspect but also in leading the scientific collaborations and tests which provided the rationale and scientific basis for this new approach to treating drug resistant epilepsy.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com.
1 Review of TSOI’s COPD Therapy Moves Forward With IND Designation (copdnewstoday.com)
2 Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell (prnewswire.com)
3 Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial | Business Wire